Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
681.58
-11.65 (-1.68%)
Jan 17, 2025, 4:00 PM EST - Market closed
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 13,450 employees as of December 31, 2023. The number of employees increased by 1,599 or 13.49% compared to the previous year.
Employees
13,450
Change (1Y)
1,599
Growth (1Y)
13.49%
Revenue / Employee
$1,029,524
Profits / Employee
$346,059
Market Cap
73.33B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | 8,100 | 700 | 9.46% |
Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
Dec 31, 2017 | 6,200 | 800 | 14.81% |
Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
Dec 31, 2014 | 2,925 | 585 | 25.00% |
Dec 31, 2013 | 2,340 | 390 | 20.00% |
Dec 31, 2012 | 1,950 | 246 | 14.44% |
Dec 31, 2011 | 1,704 | 309 | 22.15% |
Dec 31, 2010 | 1,395 | 366 | 35.57% |
Dec 31, 2009 | 1,029 | 110 | 11.97% |
Dec 31, 2008 | 919 | 237 | 34.75% |
Dec 31, 2007 | 682 | 109 | 19.02% |
Dec 31, 2006 | 573 | -15 | -2.55% |
Dec 31, 2005 | 588 | -142 | -19.45% |
Dec 31, 2004 | 730 | 86 | 13.35% |
Dec 31, 2003 | 644 | -25 | -3.74% |
Dec 31, 2002 | 669 | 94 | 16.35% |
Dec 31, 2001 | 575 | 84 | 17.11% |
Dec 31, 2000 | 491 | 54 | 12.36% |
Dec 31, 1999 | 437 | 66 | 17.79% |
Dec 31, 1998 | 371 | 101 | 37.41% |
Dec 31, 1997 | 270 | 27 | 11.11% |
Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
REGN News
- 22 hours ago - The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc. - Accesswire
- 1 day ago - Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm - Accesswire
- 3 days ago - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - PRNewsWire
- 3 days ago - Regeneron Pharmaceuticals Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm - Accesswire
- 4 days ago - Regeneron: Phase III Success In Skin Cancer For Libtayo - Seeking Alpha
- 4 days ago - Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
- 4 days ago - Jim Cramer says he supports healthcare stocks for their long-term value - CNBC
- 4 days ago - Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith - Business Wire